Harness Therapeutics, a biotechnology company based in Cambridge, UK, has recently secured an additional £4 million in funding, bringing the total amount raised to £17.6 million. The funding round saw participation from investors such as SV Health Investors, the Dementia Discovery Fund (DDF), and Takeda Ventures. With this new infusion of capital, the company aims to advance its lead programme, specifically targeting FAN1 nuclease in Huntington's Disease (HD), towards clinical trials. Harness Therapeutics, under the leadership of CEO Jan Thirkettle, is dedicated to the development of therapeutics for neurodegenerative conditions. They utilize their expertise in RNA biology and post-transcriptional regulation to develop oligonucleotide-based drugs that upregulate protein expression.
Originally established as Transine Therapeutics in 2020, Harness Therapeutics was founded by Takeda Ventures and the Dementia Discovery Fund (DDF).
In 2022, Epidarex Capital joined as an investor, further bolstering the company's resources. Initially, the company focused on advancing its IncRNA "SINEUP" platform, which allows for the upregulation of protein expression. The investments made during this period of time allowed Harness Therapeutics to develop a deep understanding of RNA biology and acquire specialized analytical capabilities. As a result, they have gained invaluable insights into the regulation of therapeutic targets and expanded their range of oligonucleotide-based tools for physiological protein upregulation.
Harness Therapeutics' primary focus is on neurodegenerative diseases, and their programmes are designed to target specific conditions like Huntington's Disease. By leveraging strong biological and genetic validation, the company aims to develop effective therapeutics that can mitigate the progression of these debilitating disorders. With the latest funding round, Harness Therapeutics is well-positioned to continue their groundbreaking work in the field of biotechnology and make meaningful contributions to the treatment of neurodegenerative diseases.